Therefore, ERCC1 may be a potential predictive but not prognostic marker and for this reason, genetic testing could personalize chemotherapy by selecting the patients who would benefit from a platinum-based treatment in bladder cancer. This evidence concerns the gene ERCC1 and urinary bladder cancer.